Compare LIND & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIND | XNCR |
|---|---|---|
| Founded | 1979 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2011 | 2013 |
| Metric | LIND | XNCR |
|---|---|---|
| Price | $29.66 | $26.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $22.25 | ★ $22.33 |
| AVG Volume (30 Days) | 731.8K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.97 | ★ 65.36 |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $10.98 | N/A |
| Revenue Next Year | $6.98 | $4.80 |
| P/E Ratio | $429.43 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $11.37 | $7.91 |
| 52 Week High | $35.00 | $30.61 |
| Indicator | LIND | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 42.07 | 71.57 |
| Support Level | $16.26 | $11.20 |
| Resistance Level | $30.00 | N/A |
| Average True Range (ATR) | 1.18 | 1.35 |
| MACD | -0.60 | 0.22 |
| Stochastic Oscillator | 2.56 | 73.02 |
Lindblad Expeditions Holdings Inc provides expedition cruising and adventure travel services. The company operates in two segments: Lindblad and Land Experiences, of which Lindblad generates the vast majority of its revenue. It offers itineraries that feature up-close encounters with wildlife, nature, history, and culture, as well as promote guest empowerment and interactivity. It operates expeditions on intimately-scaled ships and interaction between guests, crew, and the teams of scientists, naturalists, researchers, and photographers that participate in the expeditions. Lindblad operates a fleet of twelve owned expedition ships and five seasonal charter vessels under the Lindblad brand.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.